Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of bepirovirsen followed by HBV-targeted immunotherapy in chronic hepatitis B on nucleos(t)ide analogue therapy
2021-003567-10Phase 2Active
- Sponsor
- GSK
- Start
- Oct 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bepirovirsen, GSK3528869A, HBV MVA-HBV vaccine component and ChAd155-hIi-HBV vaccine in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Grade 3 adverse events. Started Oct 2021; status: active.
02
Drugs
bepirovirsenGSK3528869AHBV MVA-HBV vaccine componentChAd155-hIi-HBV vaccine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-003567-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003567-10.